Healthcare Industry News: Acute Coronary Syndrome
News Release - October 25, 2007
Momenta Pharmaceuticals Announces Appointment of Jo-Ann Beltramello as Vice President, Human ResourcesCAMBRIDGE, Mass., Oct. 25, 2007 (Healthcare Sales & Marketing Network) -- Momenta Pharmaceuticals, Inc. (NasdaqGM:MNTA ), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Jo-Ann Beltramello to the newly created position of Vice President, Human Resources.
Ms. Beltramello is an accomplished human resources executive with over 17 years of experience in the field. She joins Momenta from Multiplan, Inc., a provider of health care cost management solutions with over 2,000 employees in all fifty states. As the Chief Human Resources Officer at Multiplan, Ms. Beltramello was responsible for all human resource operations, including strategy, policies and program development. Prior to joining Multiplan, she held senior human resources roles at Oxford Global Resources, Inc., Randstad North America and Lawrence Memorial Hospital.
``Building and retaining an outstanding team at Momenta is one of our highest priorities, and we look forward to Ms. Beltramello's contribution to our human resources initiatives,'' said Craig Wheeler, President and Chief Executive Officer of Momenta. ``Jo-Ann brings significant experience in areas crucial to our evolving organization and we are very pleased to welcome her.''
Momenta is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products as well as to the discovery and development of novel drugs. The Company's most advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox(r). Momenta's first novel drug candidate is M118, a rationally engineered anticoagulant specifically designed for Acute Coronary Syndromes. Within the Company's discovery program, it is seeking to discover and develop novel therapeutics by applying its technology to better understand sugars' functions in biological processes, with an initial focus in oncology. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit the website at http://www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Source: Momenta Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.